Complimentary Webinar Focusing on Patient Registries and Observational Studies in REMS Programs

NEWARK, Del.--(BUSINESS WIRE)-- Registries and other observational studies are increasingly used in the pharmaceutical industry to inform decisions about patient safety, appropriate use, and the effectiveness of medications in the “real world.” Registries are also included in certain Risk Evaluation and Mitigation Strategies (REMS) in which specific safe use conditions must be verified and tracked. This topic will be addressed in a complimentary webinar, “Patient Registries and Observational Studies: Strategic and Operational Considerations” which will take place this Wednesday, July 13 at 12 noon EDT. This webinar is the latest in a series of monthly “Wednesday FoREMS” webinars sponsored by ParagonRx, an inVentiv Health company, and the only company specializing in pharmaceutical benefit-risk management and REMS.

The most successful registries are those that are scientifically and strategically sound, operationally cost-efficient, and sensitive to the busy medical practice settings in which they are generally deployed. This program provides insights and best practices for operating registries in the most optimal manner. Guest speaker Jeff Trotter, Executive Vice President Phase IV Development of PharmaNet, will share his in-depth knowledge on the topic. Webinar participants will learn best practices for registry operations, special considerations for registries within REMS, and insights for maximizing value and minimizing the burden of registries.

More information about registering for the “Wednesday FoREMS” webinar series can be found at Webinars will be held the second Wednesday of each month at 12 noon EDT.


Kevin Fetterman, 302-444-9861
[email protected]

KEYWORDS:   United States  North America  Delaware

INDUSTRY KEYWORDS:   Health  Biotechnology  Cardiology  Clinical Trials  Medical Devices  Oncology  Pharmaceutical  FDA



Suggested Articles

All 12 members of an FDA advisory committee voted to recommend the approval of teprotumumab for a rare, autoimmune eye disease.

Early data out of former Fierce 15 winner Gritstone Oncology have been heralded as a big win for the early-stage biotech by analysts.

Biogen will drop work on gosuranemab in progressive supranuclear palsy but continue on in Alzheimer's.